Hackensack Meridian Health Neuro-Oncologists Offer New Hope for Patients with Brain Tumors Through Groundbreaking Clinical Trials
March 09, 2022
Neuro-oncologists at Hackensack Meridian John Theurer Cancer Center (JTCC), a part of the Georgetown Lombardi Comprehensive Cancer Center, offer groundbreaking brain tumor care. At New Jersey’s top ranked cancer center, according to U.S. News & World Report, patients have access to clinical trials of the most promising novel therapies years before they become widely available without the need to travel far from home.
Brain Tumor Clinical Trials at John Theurer Cancer Center
The comprehensive neuro-oncology team at John Theurer Cancer Center offers multiple clinical trials for glioblastoma (GBM), one of the most aggressive types of brain cancer that often recurs despite standard treatments such as chemotherapy and radiation.
“The changes in DNA that allow tumors to invade the healthy brain are different in each GBM patient. By studying these changes in tumor tissue taken during an operation, we offer a highly personalized approach to cancer treatment,” said George J. Kaptain, M.D., director of Neurosurgical Oncology. “So, whether through immunotherapy, targeted therapy or chemotherapy, we strive to offer our patients rational, science-based treatments to maximize survival and minimize side effects.”
“Glioblastoma at recurrence is a particular unmet need, as there have been no drugs proven to benefit survival for these patients,” said Samuel A. Goldlust, M.D., Medical Director of Neuro-Oncology. “We are proud that in the past three months alone, we were the first brain tumor center in the United States to treat patients with recurrent GBM on trials of promising new drugs.”
The trials to which Dr. Goldlust refers include an international, phase I/II, first-in-man study of DSP 0390, a drug targeting GBM cells by interfering with cholesterol metabolism, and an international potentially pivotal study of berubicin, a similar drug to the breast cancer chemotherapy doxorubicin, optimized to target brain tumors.
In pursuit of leading-edge treatments, researchers at John Theurer Cancer Center collaborate with other leading brain tumor centers worldwide to bring new options and hope to patients in New Jersey.
To learn more about these trials (NCT 05023551), (NCT 04762069) and for a list of all brain tumor clinical trials accruing at John Theurer Cancer Center please visit:
Learn more at clinical trials at John Theurer Cancer Center or at clinicaltrials.gov.
Or call:
-
John Theurer Cancer Center: 551-996-5266